Pricing Log in Create free account

BioMarin Pharmaceutical Inc. (BMRN) vs Halozyme Therapeutics, Inc. (HALO)

BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc. are both Biotechnology companies. Halozyme Therapeutics, Inc. is the larger, with a market value of $13.8B against $10.9B — 1.3× the size. Halozyme Therapeutics, Inc. trades at the lower P/E: 34.6× against 144×. Halozyme Therapeutics, Inc. grew revenue faster over the last twelve months: 41.2% against 11.2%. Halozyme Therapeutics, Inc. has the higher net margin (24.9% vs 2.14%) and the higher return on invested capital (18.1% vs 0.97%). Across the 22 metrics below, Halozyme Therapeutics, Inc. leads on 14 and BioMarin Pharmaceutical Inc. on 8.

Valuation

Metric BMRN HALO Biotechnology median
P/E 143.89 34.61 8.50
P/S 3.10 8.59 9.71
P/B 1.67 99.54 2.13
Price to free cash flow 14.59 17.72 20.82
EV/EBITDA 46.69 22.53 0.64
EV/Sales 4.08 9.74 9.21
Earnings yield 0.69% 2.89% (33.15%)
Free cash flow yield 6.85% 5.64% (25.50%)

Profitability

Metric BMRN HALO Biotechnology median
Gross margin 76.12% 82.42% 65.16%
Operating margin 4.38% 35.90% 0.00%
Net margin 2.14% 24.86% 0.00%
Free cash flow margin 21.28% 48.46% 0.00%
Return on equity 1.18% 173.67% (56.36%)
Return on assets 0.76% 17.86% (48.04%)
Return on invested capital 0.97% 18.13% 0.00%

Growth

Metric BMRN HALO Biotechnology median
Revenue growth (TTM) 11.20% 41.15% 6.02%
EPS growth (last fiscal year) (18.55%) (25.36%) 30.26%
Revenue growth, 5-year CAGR 11.60% 39.16% 9.41%
Net income growth, 5-year CAGR (16.39%) 19.68% 0.00%

Health

Metric BMRN HALO Biotechnology median
Debt to equity 0.66 14.95 0.00
Current ratio 2.39 2.71 4.72
Net debt to EBITDA (1.99) 3.56 0.96

Dividend

Metric BMRN HALO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BMRN HALO Biotechnology median
Market cap 10.85b 13.79b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack